Cargando…
Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study
OBJECTIVE: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). METHODS: Patients with type IIIa and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051345/ https://www.ncbi.nlm.nih.gov/pubmed/35509480 http://dx.doi.org/10.1016/j.ajur.2021.09.002 |
_version_ | 1784696533369749504 |
---|---|
author | Presicce, Fabrizio Barrese, Francesco Cantiani, Andrea Filianoti, Alessio Tuzzolo, Domenico Di Palma, Paolo Lauretti, Stefano Brunori, Stefano Martini, Marco |
author_facet | Presicce, Fabrizio Barrese, Francesco Cantiani, Andrea Filianoti, Alessio Tuzzolo, Domenico Di Palma, Paolo Lauretti, Stefano Brunori, Stefano Martini, Marco |
author_sort | Presicce, Fabrizio |
collection | PubMed |
description | OBJECTIVE: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). METHODS: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire. RESULTS: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: −9.2; p<0.01), NIH-CPSI pain domain (mean difference: −5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: −5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: −12.2; p<0.01), NIH-CPSI pain domain (mean difference: −6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported. CONCLUSION: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS. |
format | Online Article Text |
id | pubmed-9051345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Second Military Medical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-90513452022-05-03 Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study Presicce, Fabrizio Barrese, Francesco Cantiani, Andrea Filianoti, Alessio Tuzzolo, Domenico Di Palma, Paolo Lauretti, Stefano Brunori, Stefano Martini, Marco Asian J Urol Original Article OBJECTIVE: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). METHODS: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire. RESULTS: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: −9.2; p<0.01), NIH-CPSI pain domain (mean difference: −5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: −5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: −12.2; p<0.01), NIH-CPSI pain domain (mean difference: −6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported. CONCLUSION: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS. Second Military Medical University 2022-04 2021-09-11 /pmc/articles/PMC9051345/ /pubmed/35509480 http://dx.doi.org/10.1016/j.ajur.2021.09.002 Text en © 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Presicce, Fabrizio Barrese, Francesco Cantiani, Andrea Filianoti, Alessio Tuzzolo, Domenico Di Palma, Paolo Lauretti, Stefano Brunori, Stefano Martini, Marco Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
title | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
title_full | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
title_fullStr | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
title_full_unstemmed | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
title_short | Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study |
title_sort | boswellia resin extract and propolis derived polyphenols in patients with type iii chronic prostatitis/chronic pelvic pain syndrome: an italian prospective multicenter study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051345/ https://www.ncbi.nlm.nih.gov/pubmed/35509480 http://dx.doi.org/10.1016/j.ajur.2021.09.002 |
work_keys_str_mv | AT presiccefabrizio boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT barresefrancesco boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT cantianiandrea boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT filianotialessio boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT tuzzolodomenico boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT dipalmapaolo boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT laurettistefano boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT brunoristefano boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy AT martinimarco boswelliaresinextractandpropolisderivedpolyphenolsinpatientswithtypeiiichronicprostatitischronicpelvicpainsyndromeanitalianprospectivemulticenterstudy |